OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Globoh Ig News
Globoh Ig News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Globoh Ig. Real-time updates on events, politics, business and more.
OBI Pharma, Inc.: OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. TAIPEI, Taiwan, Feb. 22, 2022 /PRNewswire/ -- OBI Pharma, Inc.
Source: finanznachrichten.de
OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...
Source: prnewswire.com
OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...
Source: prnewswire.com